Dimerix enters key collaboration to further boost ACTION3 trial recruitment in UK
Dimerix collaborates with UK’s National Registry of Rare Kidney Diseases to identify FSGS patients for ACTION3 trial, aiming to evaluate DMX-200 efficacy and safety. RaDaR, the largest kidney registry, holds records of 34,500 patients. The trial, currently recruiting across 16 countries, targets 286 patients over two years, with interim analysis showing DMX-200 outperforming placebo in reducing proteinuria.
Highlighted Terms
Related News
Dimerix collaborates with UK’s National Registry of Rare Kidney Diseases to identify FSGS patients for ACTION3 trial, aiming to evaluate DMX-200 efficacy and safety. RaDaR, the largest kidney registry, holds records of 34,500 patients. The trial, currently recruiting across 16 countries, targets 286 patients over two years, with interim analysis showing DMX-200 outperforming placebo in reducing proteinuria.